Alkem Laboratories has introduced NeuCeno (cenobamate) in India to treat partial-onset seizures in adults. This expands the company’s neurology portfolio, though commercial success depends on doctor adoption. Investors should watch for revenue contributions and updates regarding the company’s ongoing regulatory compliance challenges.
Alkem Laboratories has entered the Indian epilepsy treatment market with the launch of NeuCeno, a therapy containing the drug cenobamate. Designed for adults suffering from partial-onset seizures, the product is available as a once-daily oral tablet in multiple strengths ranging from 12.5 mg to 200 mg. The company aims to address a significant health need, noting that approximately 9.4 million people in India are currently living with epilepsy.
The launch is a strategic effort to strengthen Alkem’s position in the neurology segment. According to company data from clinical trials, the medication showed a reduction in seizure frequency of up to 78% in patients who had not responded well to existing treatments. Additionally, up to 30% of patients reportedly achieved seizure freedom during the maintenance phase of these studies. While these clinical outcomes are promising, the actual real-world effectiveness and adoption rates will depend on physician prescription patterns across the country.
From a financial standpoint, the immediate impact of this launch remains uncertain. Alkem has not yet disclosed pricing, sales targets, or the expected revenue contribution from NeuCeno. As a result, it is unclear how much this product will add to the company’s top line in the near term. This comes at a time when the company is navigating broader financial pressures. In its first-quarter results for the 2027 financial year, Alkem reported a 21.7% decline in net profit, partly due to rising research and development costs and tax liabilities.
Investors must also consider the company’s regulatory background. Alkem continues to manage challenges related to its manufacturing facility in Daman, which has been under an 'Official Action Indicated' (OAI) status by the US Food and Drug Administration. Regulatory issues at major manufacturing sites can often disrupt production schedules and create uncertainty for investors, making the resolution of these compliance matters a key focus for the market. Competition in the Indian pharma sector also remains intense, with many established players vying for market share in chronic therapy areas like neurology.
The path forward for Alkem with NeuCeno will depend on how quickly it can build a distribution network and achieve doctor acceptance. Investors should monitor future company disclosures regarding prescription uptake, pricing strategy, and the product's contribution to overall revenue. Furthermore, any updates on the resolution of the regulatory status at the Daman plant will remain a critical monitorable for the company's operational stability and future manufacturing flexibility.